The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J. Luke, Paul A. Moore, Roisín M. Connolly et al.|Nature Medicine|2023Cited by 135
A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaJie Wang, Bradley Sumrow, Adam S. Asch et al.|Blood|2020Cited by 25
313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasmsManish R. Patel, Susanna V. Ulahannan, Jason J. Luke et al.|Regular and Young Investigator Award Abstracts|2020Cited by 6